Vitamin C reduces deaths in early blood disorder trial
Researchers conducted the EVITA phase 2 randomized, double-blind, placebo-controlled trial in 109 patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies, assigning 55 patients to 1,000 mg/day oral vitamin C and 54 to placebo for 12 months. The primary endpoint — growth rate of precancerous or cancerous cells — was similar between groups, but vitamin C recipients showed inflammatory signaling changes linked to better outcomes and had fewer events of anemia, pneumonia, acute aseptic arthritis, and internal bleeding, though gastrointestinal problems were more frequent. At median 33.6-month follow-up there were 35 deaths (24 placebo, 11 vitamin C), and an exploratory analysis found higher survival with vitamin C, a result that needs confirmation in a larger phase 3 trial.
Phase 2 trial showed exploratory survival benefit with vitamin C supplements
Context
Decreased TET enzyme function is a known driver of some blood cancers. Researchers tested whether vitamin C boosts TET activity and affects disease course. A larger phase 3 trial could confirm the survival signal and safety profile.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked